5.98 +0.13 (2.20%)
After hours: 4:11PM EDT
|Bid||5.75 x 47300|
|Ask||6.65 x 3000|
|Day's Range||5.85 - 6.35|
|52 Week Range||5.20 - 9.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.80|
DUBLIN, Ireland and TREVOSE, Pa., June 06, 2018-- Strongbridge Biopharma plc,, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare ...
DUBLIN, Ireland and TREVOSE, Pa., May 31, 2018-- Strongbridge Biopharma plc,, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare ...
~KEVEYIS ® First Quarter 2018 Revenue of $3.9 Million~. ~Increased Full-Year 2018 Revenue Guidance for KEVEYIS from $16 to $19 Million to $18 to $20 Million~. ~MACRILEN™ Product Launch on Track for July ...
The inducement awards are being made in the form of non-qualified stock options to purchase an aggregate of 276,300 ordinary shares of the Company, and are being made as a material inducement to these individuals to enter into employment with the Company pursuant to NASDAQ Listing Rule 5635(c)(4). The exercise price of the options will be equal to the closing price of the Company’s ordinary shares on the grant date.
DUBLIN, Ireland and TREVOSE, Pa., April 26, 2018-- Strongbridge Biopharma plc,, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare ...
For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at Strongbridge BiopharmaRead More...
The company announced that it had filed the case in the United States District Court for the District of New Jersey for its Korlym (mifepristone) 300 mg tablet patent. On the day, TEVA stock registered a fall of ~3%, and Corcept Therapeutics stock fell ~0.6%. The suit was filed by Corcept after Teva filed an ANDA (Abbreviated New Drug Application) for FDA approval for selling and marketing a generic version of Korlym.
|Initiated||Cantor Fitzgerald: to Overweight||12/6/2017|
|Initiated||Oppenheimer: to Outperform||8/11/2017|
|Initiated||H.C. Wainwright: to Buy||4/25/2016|
|Initiated||Janney Capital: to Buy||12/11/2015|
|Initiated||JMP Securities: to Market Outperform||11/10/2015|
|Initiated||Stifel Nicolaus: to Buy||11/10/2015|
Full Time Employees: 66
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.